Carmustine (BCNU) has been used extensively to treat glioblastomas by injection through a
catheter placed in the cervical internal carotid artery. The technique causes severe pain to …

Retinal and CNS toxicity have been reported with infraophthalmic infusion of BCNU in the
treatment of patients with malignant gliomas. It is known, however, that the CNS toxicity can …

We treated five patients with 11 supraophthalmic infusions of BCNU at 200 mg/m2 every 2
months. All three patients with residual tumors showed marked CT response after one …

Intracarotid administration of carmustine (BCNU) is an increasingly accepted therapeutic
modality for primary brain tumors. Its beneficial effect on prolonging survival, however, is …

Early experience shows that: 1. Superselective intra-arterial catheterization above the
ophthalmic artery minimizes the orbital complications. 2. Catheterization in a distal branch …

Infusion of BCNU (Carmustine) into the internal carotid artery is being investigated as a
method of increasing the dosage of this chemotherapeutic agent to brain tumors within the …

✓ The rationale for, methodology of, and experience with intra-arterial BCNU infusion
therapy of malignant glioma are described. This approach achieves tumor levels of drug four …

We treated six patients with unilateral malignant astrocytomas with pulse doses of intra-
arterial BCNU (200 mg/m² initially, with escalating doses every 6-8 weeks) via transfemoral …

Several centers throughout the United States are now using 1, 3-bis (2-chloroethyl)-l-
nitrosurea (BCNU) in various doses administered by intracarotid infusion for the treatment of …

✓ Because of the rapid systemic clearance of BCNU (1, 3-bis-(2-chloroethyl)-1-nitrosourea),
intra-arterial administration should provide a substantial advantage over intravenous …